FIIs and DIIs are piling into these four pharma stocks. Should you follow?
While rising institutional stakes highlight growing smart-money confidence in pharma, retail investors must weigh valuations, growth drivers, and regulatory risks before deciding whether to follow suit.
Read the full story at Livemint →